These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38036064)

  • 21. Baseline Sequencing Surveillance of Public Clinical Testing, Hospitals, and Community Wastewater Reveals Rapid Emergence of SARS-CoV-2 Omicron Variant of Concern in Arizona, USA.
    Smith MF; Holland SC; Lee MB; Hu JC; Pham NC; Sullins RA; Holland LA; Mu T; Thomas AW; Fitch R; Driver EM; Halden RU; Villegas-Gold M; Sanders S; Krauss JL; Nordstrom L; Mulrow M; White M; Murugan V; Lim ES
    mBio; 2023 Feb; 14(1):e0310122. PubMed ID: 36622143
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neutralizing Activity against BQ.1.1, BN.1, and XBB.1 in Bivalent COVID-19 Vaccine Recipients: Comparison by the Types of Prior Infection and Vaccine Formulations.
    Hyun HJ; Choi MJ; Nham E; Seong H; Yoon JG; Noh JY; Cheong HJ; Kim WJ; Yoon SK; Park SJ; Gwak WS; Lee JW; Kim BG; Song JY
    Vaccines (Basel); 2023 Aug; 11(8):. PubMed ID: 37631890
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of multiplex allele-specific RT-qPCR assays for differentiation of SARS-CoV-2 Omicron subvariants.
    Li J; Cheng R; Bian Z; Niu J; Xia J; Mao G; Liu H; Wu C; Hao C
    Appl Microbiol Biotechnol; 2024 Dec; 108(1):35. PubMed ID: 38183475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SARS-CoV-2 Omicron Subvariants Do Not Differ Much in Binding Affinity to Human ACE2: A Molecular Dynamics Study.
    Nguyen HL; Nguyen TQ; Li MS
    J Phys Chem B; 2024 Apr; 128(14):3340-3349. PubMed ID: 38564480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023.
    Link-Gelles R; Ciesla AA; Roper LE; Scobie HM; Ali AR; Miller JD; Wiegand RE; Accorsi EK; Verani JR; Shang N; Derado G; Britton A; Smith ZR; Fleming-Dutra KE
    MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(5):119-124. PubMed ID: 36730051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants.
    Cho J; Shin Y; Yang JS; Kim JW; Kim KC; Lee JY
    Antiviral Res; 2023 Jun; 214():105609. PubMed ID: 37086978
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An updated atlas of antibody evasion by SARS-CoV-2 Omicron sub-variants including BQ.1.1 and XBB.
    He Q; Wu L; Xu Z; Wang X; Xie Y; Chai Y; Zheng A; Zhou J; Qiao S; Huang M; Shang G; Zhao X; Feng Y; Qi J; Gao GF; Wang Q
    Cell Rep Med; 2023 Apr; 4(4):100991. PubMed ID: 37019110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum neutralization of SARS-CoV-2 Omicron BA.2, BA.2.75, BA.2.76, BA.5, BF.7, BQ.1.1 and XBB.1.5 in individuals receiving Evusheld.
    Zhao Q; Wang X; Zhang Z; Liu X; Wang P; Cao J; Liang Q; Qu J; Zhou M
    J Med Virol; 2023 Jul; 95(7):e28932. PubMed ID: 37403923
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants.
    Tamura T; Ito J; Uriu K; Zahradnik J; Kida I; Anraku Y; Nasser H; Shofa M; Oda Y; Lytras S; Nao N; Itakura Y; Deguchi S; Suzuki R; Wang L; Begum MM; Kita S; Yajima H; Sasaki J; Sasaki-Tabata K; Shimizu R; Tsuda M; Kosugi Y; Fujita S; Pan L; Sauter D; Yoshimatsu K; Suzuki S; Asakura H; Nagashima M; Sadamasu K; Yoshimura K; Yamamoto Y; Nagamoto T; Schreiber G; Maenaka K; ; Hashiguchi T; Ikeda T; Fukuhara T; Saito A; Tanaka S; Matsuno K; Takayama K; Sato K
    Nat Commun; 2023 May; 14(1):2800. PubMed ID: 37193706
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion.
    Li P; Liu Y; Faraone JN; Hsu CC; Chamblee M; Zheng Y-M; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Li J; Gumina RJ; Liu S-L
    mBio; 2024 May; 15(5):e0075124. PubMed ID: 38591890
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level.
    Akerman A; Milogiannakis V; Jean T; Esneau C; Silva MR; Ison T; Fichter C; Lopez JA; Chandra D; Naing Z; Caguicla J; Li D; Walker G; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Condylios A; Yeang M; Wong M; Foster CSP; Sato K; Lee S; Song Y; Mao L; Sigmund A; Phu A; Vande More AM; Hunt S; Douglas M; Caterson I; Britton W; Sandgren K; Bull R; Lloyd A; Triccas J; Tangye S; Bartlett NW; Darley D; Matthews G; Stark DJ; Petoumenos K; Rawlinson WD; Murrell B; Brilot F; Cunningham AL; Kelleher AD; Aggarwal A; Turville SG
    EBioMedicine; 2023 Apr; 90():104545. PubMed ID: 37002990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Editorial: The XBB.1.5 ('Kraken') Subvariant of Omicron SARS-CoV-2 and its Rapid Global Spread.
    Parums DV
    Med Sci Monit; 2023 Feb; 29():e939580. PubMed ID: 36722047
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vaccine effectiveness against hospitalisation estimated using a test-negative case-control study design, and comparative odds of hospital admission and severe outcomes with COVID-19 sub-lineages BQ.1, CH.1.1. and XBB.1.5 in England.
    Kirsebom FCM; Harman K; Lunt RJ; Andrews N; Groves N; Abdul Aziz N; Hope R; Stowe J; Chand M; Ramsay M; Dabrera G; Kall M; Bernal JL
    Lancet Reg Health Eur; 2023 Dec; 35():100755. PubMed ID: 38115965
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sera from breakthrough infections with SARS-CoV-2 BA.5 or BF.7 showed lower neutralization activity against XBB.1.5 and CH.1.1.
    Liu S; Liang Z; Nie J; Gao WB; Li X; Zhang L; Yu Y; Wang Y; Huang W
    Emerg Microbes Infect; 2023 Dec; 12(2):2225638. PubMed ID: 37313604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion.
    Planas D; Staropoli I; Michel V; Lemoine F; Donati F; Prot M; Porrot F; Guivel-Benhassine F; Jeyarajah B; Brisebarre A; Dehan O; Avon L; Boland WH; Hubert M; Buchrieser J; Vanhoucke T; Rosenbaum P; Veyer D; Péré H; Lina B; Trouillet-Assant S; ; Hocqueloux L; Prazuck T; Simon-Loriere E; Schwartz O
    bioRxiv; 2024 Feb; ():. PubMed ID: 38045308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genomic surveillance reveals early detection and transition of delta to omicron lineages of SARS-CoV-2 variants in wastewater treatment plants of Pune, India.
    Rajput V; Pramanik R; Malik V; Yadav R; Samson R; Kadam P; Bhalerao U; Tupekar M; Deshpande D; Shah P; Shashidhara LS; Boargaonkar R; Patil D; Kale S; Bhalerao A; Jain N; Kamble S; Dastager S; Karmodiya K; Dharne M
    Environ Sci Pollut Res Int; 2023 Dec; 30(56):118976-118988. PubMed ID: 37922087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular Epidemiology of SARS-CoV-2 Omicron Sub-Lineages Isolated from Turkish Patients Infected with COVID-19.
    Sayan M; Arikan A; Sanlidag E
    Viruses; 2023 Apr; 15(5):. PubMed ID: 37243152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune evasion of neutralizing antibodies by SARS-CoV-2 Omicron.
    Wang L; Møhlenberg M; Wang P; Zhou H
    Cytokine Growth Factor Rev; 2023 Apr; 70():13-25. PubMed ID: 36948931
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Wastewater Genomic Surveillance Captures Early Detection of Omicron in Utah.
    Gupta P; Liao S; Ezekiel M; Novak N; Rossi A; LaCross N; Oakeson K; Rohrwasser A
    Microbiol Spectr; 2023 Jun; 11(3):e0039123. PubMed ID: 37154725
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Divergent trajectory of replication and intrinsic pathogenicity of SARS-CoV-2 Omicron post-BA.2/5 subvariants in the upper and lower respiratory tract.
    Hu B; Chan JF; Liu Y; Liu H; Chen YX; Shuai H; Hu YF; Hartnoll M; Chen L; Xia Y; Hu JC; Yuen TT; Yoon C; Hou Y; Huang X; Chai Y; Zhu T; Shi J; Wang Y; He Y; Cai JP; Zhou J; Yuan S; Zhang J; Huang JD; Yuen KY; To KK; Zhang BZ; Chu H
    EBioMedicine; 2024 Jan; 99():104916. PubMed ID: 38101297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.